Date of Presentation
5-5-2022 12:00 AM
College
School of Osteopathic Medicine
Poster Abstract
Bladder cancer represents the 6th most common for men and is classified into muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC). NMIBC (T1, Ta, Tis), accounting for approximately 75% of new bladder cancer diagnoses, is limited to the mucosa, submucosa, and lamina propria. Studies have approximated the rate of recurrence in NMIBC between 50 - 70%, which sometimes progresses to muscle invasive disease. Management of NMIBC ranges from surveillance, intravesical chemotherapy to radical cystectomy (RC) and is dependent upon the TNM staging and grading of the tumor. Clinically, staging is determined via imaging, physical exam, and histology on transurethral resection of bladder tumor (TURBT), while pathologic grading is determined via radical cystectomy and pelvic lymph node dissection (PLND).
PLND has been shown to have a therapeutic benefit in localized bladder cancer when done in conjunction with RC, in addition to diagnostic and therapeutic elements. While the relationship between PLND and MIBC has been studied extensively, the role of lymph node (LN) dissection during RC for NMIBC remains unclear, with few studies and conflicting results. Furthermore, although lymph node metastasis has been found to occur in up to 16.2% of NMIBC patients, its reported that nearly half have insufficient PLND during RC and 16.6% have no PLND done at all. The aim of this data analysis is to determine the predictive factors and outcomes for LN positive patients undergoing PLND with RC in NMIBC.
Keywords
Neoplasms, Urologic Neoplasms, Lymph Node Excision, Cystectomy
Disciplines
Male Urogenital Diseases | Medicine and Health Sciences | Neoplasms | Oncology | Surgical Procedures, Operative | Urogenital System | Urology
Document Type
Poster
Included in
Male Urogenital Diseases Commons, Neoplasms Commons, Oncology Commons, Surgical Procedures, Operative Commons, Urogenital System Commons, Urology Commons
Factors and Outcomes Contributing to Pelvic Lymph Node Dissection in Non-Muscle Invasive Bladder Cancer
Bladder cancer represents the 6th most common for men and is classified into muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC). NMIBC (T1, Ta, Tis), accounting for approximately 75% of new bladder cancer diagnoses, is limited to the mucosa, submucosa, and lamina propria. Studies have approximated the rate of recurrence in NMIBC between 50 - 70%, which sometimes progresses to muscle invasive disease. Management of NMIBC ranges from surveillance, intravesical chemotherapy to radical cystectomy (RC) and is dependent upon the TNM staging and grading of the tumor. Clinically, staging is determined via imaging, physical exam, and histology on transurethral resection of bladder tumor (TURBT), while pathologic grading is determined via radical cystectomy and pelvic lymph node dissection (PLND).
PLND has been shown to have a therapeutic benefit in localized bladder cancer when done in conjunction with RC, in addition to diagnostic and therapeutic elements. While the relationship between PLND and MIBC has been studied extensively, the role of lymph node (LN) dissection during RC for NMIBC remains unclear, with few studies and conflicting results. Furthermore, although lymph node metastasis has been found to occur in up to 16.2% of NMIBC patients, its reported that nearly half have insufficient PLND during RC and 16.6% have no PLND done at all. The aim of this data analysis is to determine the predictive factors and outcomes for LN positive patients undergoing PLND with RC in NMIBC.